MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis

• Published in: Haematologica (Roma) Vol. 105; no. 2; pp. 424 - 434
• Main Authors: Vermaat, Joost S, Somers, Sebastiaan F, de Wreede, Liesbeth C, Kraan, Willem, de Groen, Ruben A L, Schrader, Anne M R, Kerver, Emile D, Scheepstra, Cornelis G, Berenschot, Henriëtte, Deenik, Wendy, Wegman, Jurgen, Broers, Rianne, de Boer, Jan-Paul D, Nijland, Marcel, van Wezel, Tom, Veelken, Hendrik, Spaargaren, Marcel, Cleven, Arjen H, Kersten, Marie José, Pals, Steven T
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01.02.2020
• Subjects: Epstein-Barr Virus Infections - genetics; Herpesvirus 4, Human; Humans; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - genetics; Mutation; Myeloid Differentiation Factor 88 - genetics; Prognosis

The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic rearrangements of as drivers of lymphomagenesis. A subset of DLBCL, however, is characterized by activating mutations in We investigated...